Samir D. Undevia - Concepedia

Author

Samir D. Undevia

University of Chicago

Also Known As

S UNDEVIA, S. D. Undevia, S. Undevia, S.D. Undevia, Samir D Undevia, Samir D. Undevia, Samir Undevia

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

University of Chicago Cancer Research Center Memorial Sloan Kettering Cancer Center Washington University in St. Louis University of Chicago Medical Center

About

Samir D. Undevia is an author at University of Chicago specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	20	1.2K
2	Health Sciences	4	4	665
3	Public Health	1	1	13
4	Biochemistry	1	1	18
5	Cell Biology	1	1	22

Samir D. Undevia

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan Federico Innocenti, Samir D. Undevia, Lalitha Iyer, Journal of Clinical Oncology	2004	946
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas Robert G. Maki, David R. D’Adamo, Mary Louise Keohan, Journal of Clinical Oncology Surgical OncologySarcoma SubtypeMalignant DiseaseMedicineDaily Oral Sorafenib	2009	569
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial Gary K. Schwartz, William D. Tap, Li-Xuan Qin, The Lancet Oncology	2013	186
Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment Michael L. Maitland, Kristen Kasza, Theodore Karrison, Clinical Cancer Research	2009	172
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the <i>UGT1A1</i> Genotype of Patients With Cancer Federico Innocenti, Richard L. Schilsky, Jacqueline Ramı́rez, Journal of Clinical Oncology	2014	137
Primary Tumor Necrosis Predicts Distant Control in Locally Advanced Soft-Tissue Sarcomas After Preoperative Concurrent Chemoradiotherapy Dhara MacDermed, Luke Miller, Terrance D. Peabody, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyMalignant DiseasePreoperative Concurrent ChemoradiotherapyMedicinePathology	2009	99
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma Warren Chow, Paul Frankel, Chris Ruel, Cancer	2019	76
Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients Ezra E.W. Cohen, Kehua Wu, Christine Hartford, Clinical Cancer Research	2012	74
Histologic response of dose‐intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high‐risk soft tissue sarcomas Christopher W. Ryan, Anthony Montag, Janet Hosenpud, Cancer	2008	71
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine Samir D. Undevia, Hedy L. Kindler, Linda Janisch, Annals of Oncology ChromatinMedicinal ChemistryMedicinePharmacotherapyPharmacology	2004	69

Page 1